LRMR
Larimar Therapeutics Inc
NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY
$4.06
-6.45% today
Updated 2026-04-30
Market cap
$461.24M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.27
Dividend yield
—
52W range
$2 – $6
Volume
5.0M
Larimar Therapeutics Inc (LRMR) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | — | $10.99M | $38.14M | $117.52M | $189.11M | $131.62M | $105.51M | $121.76M | $5.20M | $104.69M | $78.67M | $126.41M | $95.94M | $200.22M |
| Cash & equivalents | — | $9.94M | $35.52M | $58.10M | $35.59M | $32.35M | $40.78M | $49.33M | $1.01M | $68.15M | $70.10M | $26.82M | $26.75M | $33.22M |
| Current assets | — | $10.32M | $37.36M | $117.20M | $188.11M | $130.90M | $104.92M | $121.33M | $4.75M | $97.95M | $72.20M | $120.74M | $90.17M | $195.30M |
| Total liabilities | — | $2.93M | $2.92M | $13.08M | $20.00M | $9.89M | $27.29M | $28.49M | $5.89M | $14.99M | $14.25M | $15.50M | $14.21M | $28.41M |
| Current liabilities | — | $2.93M | $2.92M | $6.90M | $16.54M | $9.89M | $7.29M | $13.31M | $5.89M | $8.99M | $8.85M | $10.71M | $9.51M | $24.36M |
| Long-term debt | — | — | — | — | $3.45M | — | $20.00M | $15.19M | $8.46M | — | — | — | — | — |
| Shareholder equity | — | $8.06M | $35.22M | $104.44M | $169.11M | $121.73M | $78.22M | $93.27M | $-694000.00 | $89.69M | $64.41M | $110.90M | $81.72M | $171.81M |
| Retained earnings | — | $-54.88M | $-68.91M | $-105.39M | $-179.67M | $-237.55M | $-289.58M | $-350.94M | $-23.13M | $-65.61M | $-116.25M | $-151.60M | $-188.55M | $-269.16M |
| Accounts receivable | — | — | $1.62M | — | $1.32M | $347000.00 | $946000.00 | $1.54M | $158000.00 | $32000.00 | $208000.00 | — | — | $1.05M |
| Inventory | — | — | — | — | — | $1.00 | — | — | $3.16M | $-32000.00 | $-208000.00 | — | — | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — | — | — | — | — |